Marin Anna, Budson Andrew E
Center for Translational Cognitive Neuroscience, Veterans Affairs Boston Healthcare System, Boston, MA, United States.
Department of Behavioral Neuroscience, Boston University Aram V. Chobanian & Edward Avedisian School of Medicine, Boston, MA, United States.
Fac Rev. 2023 Oct 10;12:24. doi: 10.12703/r/12-24. eCollection 2023.
As the rates of Alzheimer's Disease (AD) increase in the world due to the aging of the population, research has made tremendous advances to target the two hallmark pathologies of AD: amyloid-β (Aβ) plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Here, we discuss recent advances in the clinical evaluation and management of AD, with a focus on new hypotheses related to the etiology of AD and new evidence related to AD-mimicking neurodegenerative diseases. Though recent clinical studies suggest anti-amyloid disease modifying agents may slow the progression of AD, there is currently no medication that stops it. Moreover, slowing the progression will result in more individuals in the mild cognitive impairment (MCI) and mild dementia stages of AD. Given this reality, we evaluate the development of non-pharmacological strategies to help sustain cognitive function and quality of life.
随着全球人口老龄化导致阿尔茨海默病（AD）发病率上升，针对AD的两大标志性病理特征——淀粉样β（Aβ）斑块沉积和过度磷酸化tau蛋白的神经原纤维缠结，研究取得了巨大进展。在此，我们讨论AD临床评估和管理的最新进展，重点关注与AD病因相关的新假说以及与AD模拟神经退行性疾病相关的新证据。尽管最近的临床研究表明抗淀粉样蛋白疾病修饰剂可能会减缓AD的进展，但目前尚无药物能够阻止其发展。此外，减缓疾病进展将导致更多个体处于AD的轻度认知障碍（MCI）和轻度痴呆阶段。鉴于这一现实，我们评估有助于维持认知功能和生活质量的非药物策略的发展。
